The primary endpoint was the best PSA response rate which was defined according to the Prostate Cancer Clinical Trials Working Group-3 (PCWG3) as the proportion of patients achieving a ≥50% decline in PSA from baseline [28]. Here, KLK3 is linked to prostate cancer.